Calendar  Volatility Report 4/27/2010  Volatility Report 4/28/2010  Volatility Report 4/29/2010  
VIVUS, Inc. (VVUS) is at an implied volatility extreme high of 112.29% that is greater than 90.41% of past values prior to 4/28/2010 (Close Price 9.69). On prior close, 4/27/2010, the implied volatility was 72.98% and at the 41.79 percentile. Closing price was 9.56.

Today's News on VIVUS, Inc.

What Analysts Won't Tell You About Arena

Orexigen Finds A Cautious Partner

Arena Pharma: Understanding the Market for Anti-Obesity Drugs

Nasdaq stocks posting largest percentage increases

Orexigen signs $1 billion obesity drug deal
[AP] - Shares of Orexigen Therapeutics Inc. surged Thursday after the drugmaker said it signed a $1 billion co-development agreement for its experimental obesity drug Contrave with Takeda Pharmaceuticals.

A service of Trotter Trading Systems
Tuesday, Sep 7, 2010